Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 4/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13539375 | 0.85 | LMNA (0.72) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL16012504 | 0.85 | LMNA (0.72) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL26272949 | 0.85 | LMNA (0.72) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL31258864 | 0.85 | LMNA (0.72) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL10417106 | 0.85 | LMNA (0.72) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL10892082 | 0.83 | MAPT (0.64) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL5667926 | 0.83 | MAPT (0.64) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL5663208 | 0.81 | MAPT (0.61) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL16841293 | 0.79 | LMNA (0.64) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL16841382 | 0.79 | LMNA (0.64) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-11-10 | — | — | US | disclosed |
| EP-1535923-A1 | Synthesis of acyclic nucleoside derivatives | Medivir Aktiebolag (SE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1131323-B1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2005-04-27 | — | — | EP | disclosed |
| US-6878844-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-04-12 | — | — | US | disclosed |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-12-09 | — | — | US | disclosed |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-02-05 | — | — | US | disclosed |
| US-6613936-B1 | Herpes and retroviral infections; diester derivatives of H2G bearing specific combinations of an amino acid ester and a fatty acid ester, improved oral bioavailability; 9-(2-(butyryloxymethyl)-4-(L-isoleucyloxy)butyl)guanine | MEDIVIR AB (SE) | 2003-09-02 | — | — | US | disclosed |
| EP-0971923-B1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1131323-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 2001-09-12 | — | — | EP | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| WO-2000008025-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| EP-0971923-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998034917-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | LMNA 1179/4885KDM4E 4410/4885DUSP3 4032/4885 |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | LMNA 1179/4885KDM4E 4410/4885DUSP3 4032/4885 |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | ASNS, NUDT1, PNP | LMNA 1262/4885KDM4E 4268/4885DUSP3 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.